AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15842140
Drug: Comprehensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive therapy without SN33
Trial: 12855972
Drug: Treatment Group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Group (prophylactic macular photocoagulation)
Trial: 12855972
Drug: No Treatment
RxNorm normalized name: NO
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No Treatment Group (control)
Trial: 10569644
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (LA) 600 mg/d
Trial: 10569644
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LA and AT
Trial: 7063290
Drug: Flunisolide aerosol
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flunisolide aerosol (0.5 mg twice a day)
Trial: 29381789
Drug: Automated Self‐Administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated Self‐Administered 24‐h recalls (ASA24s)
Trial: 24707021
Drug: Lovaza (3360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovaza (3360 mg docosahexaenoic acid + eicosapentaenoic acid per day)
Trial: 10220696
Drug: Steroid pretreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid pretreatment (methylprednisolone, 30 mg/kg)
Trial: 7880703
Drug: Bupivacaine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 50 mg
Trial: 7880703
Drug: Fentanyl in
RxNorm normalized name: fentanyl Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl in 0.25% bupivacaine (25 mg)
Trial: 7880703
Drug: Fentanyl in
RxNorm normalized name: fentanyl Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl in 0.125% bupivacaine (12.5 mg)
Trial: 638249
Drug: Low-dose 'concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose 'concentration x time' (C x T) schedule of 1 mg every 12 hr for 3 days
Trial: 638249
Drug: Single injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injections of 12 mg/sq m/dose
Trial: 22465047
Drug: 0.006 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.006 mg/kg/day of GH subcutaneously (group A, n=60)
Trial: 19204509
Drug: HBOC-201 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBOC-201 (up to ten 30 g Hb units)
Trial: 15059636
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 400 IU daily for 6 months
Trial: 7538815
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interleukin-6 (rhIL-6) maintenance therapy
Trial: 2177394
Drug: Carboplatin (CP)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (CP) 167‐436 mg/m2 by intravenous infusion, repeated every 4 weeks, 2‐4 cycles
Trial: 2177394
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy containing CP (CE: CP + VP ‐ 16)
Trial: 2177394
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy containing DDP (PE: DDP + VP ‐ 16)
Trial: 2177394
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy containing CP (CAC: CP + adriamycin + cyclophosphamide)
Trial: 2177394
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy containing DDP (PAC: DDP + adriamycin + cyclophosphamide)
Trial: 7406654
Drug: Methadyl acetate
RxNorm normalized name: Methadyl acetate
DrugBank: Methadyl acetate (DB01433)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadyl acetate administered on Friday, starting dose identical to previously established methadone dose, flexible thereafter.
Trial: 7406654
Drug: Daily methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily methadone comparison group.
Trial: 30229398
Drug: Enteric-coated mycophenolate
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated mycophenolate sodium (EC-MPS) administered to elderly renal transplant recipients
Trial: 21070781
Drug: Budesonide 9
RxNorm normalized name: budesonide 9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 9 mg/day (once daily)
Trial: 21070781
Drug: Mesalamine 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine 4.5 g/day
Trial: 21070781
Drug: Budesonide 3
RxNorm normalized name: budesonide 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 3 mg/day (3 times daily)
Trial: 19092729
Drug: Valdecoxib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib and parecoxib (40 mg IV every 6 hours on day one postoperative)
Trial: 11218929
Drug: Waterless hand
RxNorm normalized name: ALCOHOL 62 mL in 100 mL TOPICAL GAS [WATERLESS HAND SANITIZER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waterless hand preparation (HP) containing 61% ethyl alcohol, 1% CHG, and emollients
Trial: 9232709
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy in health care centre
Trial: 9232709
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy in day-care clinic
Trial: 8358075
Drug: New flavoured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New flavoured PEG solution for gut lavage
Trial: 8358075
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation (2‐day semi‐liquid diet, laxatives and cleansing enemas)
Trial: 3313678
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (5-ASA) 1500 mg slow-release/day (Pentasa)
Trial: 1062910
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of ferrous iron daily
Trial: 27376411
Drug: eCBT (exposure-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eCBT (exposure-based cognitive behavioural therapy)
Trial: 24939817
Drug: 24h pretreatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24h pretreatment with dexamethasone (0.5 mg/kg/dose, q6h, total of six doses; n = 66)
Trial: 24939817
Drug: 6h pretreatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6h pretreatment with dexamethasone (total of three doses; n = 58)
Trial: 12460127
Drug: Manual-guided outpatient
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual-guided outpatient treatments
Trial: 9806127
Drug: Tenoxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam (20 mg daily, n = 23)
Trial: 9806127
Drug: L-EE (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-EE (1 tablet containing 0.05 mg + 2.5 mg, 3 times daily, n = 25)
Trial: 2536211
Drug: Extruded meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extruded meal (40 g) with milk, 58Fe (1.253 mg) and 67Zn (5.13 mg) administered
Trial: 2536211
Drug: Nonextruded meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonextruded meal (40 g) with milk, 58Fe (1.253 mg) and 67Zn (5.13 mg) administered
Trial: 31987796
Drug: Synbiotic agents
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic agents (fructo-oligosaccharides, 4 g twice per day, plus Bifidobacterium animalis subspecies lactis BB-12; n=55)
Trial: 28099236
Drug: Perfluorohexane treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfluorohexane treatment (endotracheal instillation) in addition to conventional treatment.
Trial: 28099236
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (anti-infection, nutritional support, antishock measures, and supportive treatment).
Trial: 23521170
Drug: Topical ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketamine (0.4 ml, 20 mg)
Trial: 23521170
Drug: Topical tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tramadol (0.8 ml)
Trial: 23521170
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (5 ml saline)
Trial: 22039471
Drug: Rituximab 500
RxNorm normalized name: riTUXimab 500 MG in 50 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 500 mg/m², given twice two weeks apart
Trial: 17524529
Drug: Meningococcal polysaccharide
RxNorm normalized name: meningococcal polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal polysaccharide vaccines
Trial: 1119396
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg digoxin daily
Trial: 1119396
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg digoxin daily
Trial: 1119396
Drug: Variable doses
RxNorm normalized name: methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Variable doses of digoxin (0 to 0.75 mg)
Trial: 25637007
Drug: Topical coconut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical coconut oil applications
Trial: 18596389
Drug: Sorafenib as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib as a single-agent therapy
Trial: 18596389
Drug: Sorafenib in
RxNorm normalized name: Product containing sorafenib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib in combination with carboplatin and paclitaxel
Trial: 11095456
Drug: Weekly GH
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly GH dose (natural log transformation)
Trial: 11095456
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of GH injections per week
Trial: 3103416
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (2 mg/kg daily of elemental zinc supplement as acetate)
Trial: 30524185
Drug: Curettage plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curettage plus NCH gel (intervention group)
Trial: 22012196
Drug: IVIG +
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG + prednisolone (PSL) therapy
Trial: 22012196
Drug: IVIG therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG therapy
Trial: 9737352
Drug: Menatetrenone (MK-4)
RxNorm normalized name: menatetrenone
DrugBank: Menatetrenone (DB12148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menatetrenone (MK-4) 45 mg daily for 12 months
Trial: 10334139
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP); total dosage, 1,000 microg/d
Trial: 2142486
Drug: Teicoplanin 400
RxNorm normalized name: Teicoplanin 400 mg powder for solution for injection vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 400 mg per day
Trial: 282051
Drug: Indomethacin with
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin with diuretic or propranolol therapy
Trial: 23490226
Drug: MF/F 100/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF/F 100/10 μg
Trial: 23490226
Drug: MF/F 200/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF/F 200/10 μg
Trial: 23490226
Drug: MF/F 400/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF/F 400/10 μg
Trial: 23490226
Drug: MF-MDI 200
RxNorm normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF-MDI 200 μg
Trial: 23490226
Drug: MF 200
RxNorm normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF 200 μg via DPI
Trial: 19628108
Drug: Chia seed
RxNorm normalized name: CHIA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chia seed (CS) 25 g mixed in 0.25 L water twice daily for 12 weeks
Trial: 19628108
Drug: Placebo (P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (P) 25 g mixed in 0.25 L water twice daily for 12 weeks
Trial: 9261749
Drug: Individual psychotherapy
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual psychotherapy and psychopharmacological treatment (study group)
Trial: 7952799
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg furosemide preadsorbed onto 160 mg charcoal
Trial: 7952799
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg furosemide preadsorbed onto 200 mg charcoal
Trial: 7952799
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg furosemide only (reference)
Trial: 24144196
Drug: levomilnacipran ER
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levomilnacipran ER 40 mg/day
Trial: 24144196
Drug: levomilnacipran ER
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levomilnacipran ER 80 mg/day
Trial: 21155174
Drug: 9-valent pneumococcal
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV9)
Trial: 21155174
Drug: 9-valent pneumococcal
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV9) in HIV-infected children
Trial: 16643909
Drug: Doppler assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doppler assessment of blood flow to the follicle and the endometrium; serum concentrations of biochemical markers such as anti‐Müllerian hormone, inhibin B, FSH, LH, and P
Trial: 8857016
Drug: Elevated cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated cardiac troponin T levels (> 0.1 ng/mL)
Trial: 8857016
Drug: Lower cardiac
RxNorm normalized name: Leonurus cardiaca flowering top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower cardiac troponin T levels (≤ 0.1 ng/mL)
Trial: 1536246
Drug: Betamethasone (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (two doses of 12 mg, 24 hours apart)
Trial: 6401442
Drug: Oral nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nifedipine 10‐20 mg
Trial: 31378506
Drug: Low-Intensity Extracorporeal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Intensity Extracorporeal Shockwave Therapy (Li-ESWT)
Trial: 30439309
Drug: cf‐DNA in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cf‐DNA in sepsis group (μg/L): 1,438.0 (1,154.0, 1,576.0)
Trial: 30439309
Drug: cf‐DNA in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cf‐DNA in severe sepsis group (μg/L): 2,595.0 (2,162.0, 5,198.0)
Trial: 30439309
Drug: PCT in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT in sepsis group (μg/L): 5.80 (3.28, 8.85)
Trial: 30439309
Drug: PCT in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT in severe sepsis group (μg/L): 17.53 (8.40, 29.61)
Trial: 24379169
Drug: CPAP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP and a 6-month behavioral medicine intervention targeting physical activity (PA) and eating behavior (EB)
Trial: 18422060
Drug: Mean corpuscular
RxNorm normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean corpuscular hemoglobin concentration (MCHC) in patients with hereditary spherocytosis (35.67±1.33 g/dl)
Trial: 15209811
Drug: Prednisone 20
RxNorm normalized name: prednisone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 20 mg oral daily
Trial: 9704373
Drug: 100 units
RxNorm normalized name: heparin 100 units/mL injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 units of botulinum toxin type A (second injection)
Trial: 20070280
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg EPs‐7630
Trial: 20070280
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg EPs‐7630
Trial: 20070280
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg EPs‐7630
Trial: 12589167
Drug: Quadruple immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple immunosuppressive therapy (interleukin (IL)‐2 receptor antibody, tacrolimus, mycophenolate mofetil, and prednisone)
Trial: 1280802
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ibuprofen plus 30 mg codeine
Trial: 26303195
Drug: Fiber intake
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber intake >15 g/1000 kcal
Trial: 18507656
Drug: Atropine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (5 mg intravenously)
Trial: 18507656
Drug: Atropine (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (administered at the time of the nadir)
Trial: 18507656
Drug: Fingolimod (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod (5 mg orally)
Trial: 16132406
Drug: Octreotide 0.1
RxNorm normalized name: octreotide 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 0.1 mg subcutaneously 3 times/day for a total of 7 days
Trial: 11950022
Drug: Telephone administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telephone administration of WOMAC LK3.0 Index
Trial: 10225505
Drug: Cognitive-Behavior Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavior Therapy (Trauma Treatment Protocol; TTP)
Trial: 310917
Drug: Prophylactic digitalization
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic digitalization with digoxin (1 or 1.5 mg before operation, 0.25 mg daily postoperatively)
Trial: 310917
Drug: Digoxin dosage
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin dosage comparison (1 mg vs. 1.5 mg)
Trial: 31358243
Drug: Abdominal massage
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal massage (15-min video-guided training, performed twice a day for 4 weeks)
Trial: 29354953
Drug: Wrist‐ankle needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wrist‐ankle needle therapy combined with patient controlled intravenous analgesia (PCIA)
Trial: 26164267
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment (five different compounds)
Trial: 21396901
Drug: 9 valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 valent pneumococcal conjugate vaccines (3 doses in infancy)
Trial: 21396901
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose at 9 months or early in the second year of life (suggested for evaluation)
Trial: 21396901
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not receiving the vaccine)
Trial: 17634547
Drug: 2.5 mg/d
RxNorm normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/d tibolone for 14 days
Trial: 1404819
Drug: 20 mg/d
RxNorm normalized name: Valtoco, 20 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/d of tacrine
Trial: 1404819
Drug: 40 mg/d
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/d of tacrine
Trial: 1404819
Drug: 80 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/d of tacrine
Trial: 3932677
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (Group II)